Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × EGFR-mutated NSCLC (Disorder) × osimertinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 7 Neoplasms 3 Lung Neoplasms 3 Thoracic Neoplasms 2 Respiratory Tract Neoplasms 2 Respiratory Tract Diseases 2 Neoplasms, Nerve Tissue 2 Neoplasms by Site 2 Neoplasms by Histologic Type 2 Lung Diseases 2 Carcinoma, Bronchogenic 2 Carcinoma 2 Bronchial Neoplasms 2 Adenocarcinoma 2 Neoplasm Metastasis 1 NSCLC 1 Mesothelioma, Malignant 1 Hemangioendothelioma, Epithelioid 1 EGFR-mutated NSCLC (Disorder) 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03418532 2023-03-23

MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC

Molecular Partners AG

Phase 1 Terminated

EGFR-mutated NSCLC (Disorder)

Data powered by HemOnc (CC BY 4.0) Colophon ⚡